Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nanjing Port Co Ltd
SZSE:002040
|
CN |
|
Whirlpool Corp
NYSE:WHR
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
Z
|
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
|
15.1B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View
Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Zhejiang Jiuzhou Pharmaceutical Co Ltd is 34.6%, which is above its 3-year median of 34.6%.
Over the last 3 years, Zhejiang Jiuzhou Pharmaceutical Co Ltd’s Gross Margin has increased from 34.4% to 34.6%. During this period, it reached a low of 30.9% on Dec 31, 2024 and a high of 37.6% on Sep 30, 2023.